This article sets out the methods of procurement through the Electronic Public Administration Market in the national health system, characterized by measures to rationalize expenditure with respect to the reduction of financial resources allocated to this sector and by the need to procure innovative high-cost pharmaceuticals both in the production phase that of acquisition. In this context, two specific methods of acquisition launched on the MEPA are analyzed, such as the framework agreement and the convention that make it possible to make the procurement of innovative pharmaceuticals at a competitive cost more flexible through measures able to favor purchases for the benefit of healthcare institutions, and broaden the participation of economic operators.
The objective of this article is to highlight the latest soft and hard skills of the operators involved in different ways in the digitized and centralized procedures in the procurement of drugs. In conclusion, the measures to be implemented with regard to the new needs and therapeutic pathways to be undertaken will be highlighted.
